[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "dahhamalsoud.github.io",
    "section": "",
    "text": "This is a Quarto website.\nTo learn more about Quarto websites visit https://quarto.org/docs/websites.\n\n1 + 1\n\n[1] 2"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "Dahham Alsoud",
    "section": "",
    "text": "About this site\n\n1 + 1\n\n[1] 2"
  },
  {
    "objectID": "publications.html",
    "href": "publications.html",
    "title": "Publications",
    "section": "",
    "text": "Breaking the therapeutic ceiling in drug development in ulcerative colitis.\nThe Lancet Gastroenterology and Hepatology PMID: 34019798\nUtility of the serum-based Endoscopic Healing Index in monitoring therapeutic response in ulcerative colitis.\nThe American Journal of Gastroenterology PMID: 37753938\nCalibration, clinical utility and specificity of clinical decision support tools in inflammatory bowel disease.\nin revision\nReal-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis.\nJournal of Crohn’s and Colitis PMID: 3533353\nReal-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study.\nInflammatory Bowel Diseases PMID: 38215029 Analysis notebook\nBest practice for therapeutic drug monitoring of infliximab: position statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.\nTherapeutic Drug Monitoring accepted\nMonitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?\nCurrent Opinion in Pharmacology PMID: 33039940\nBiomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises.\nCurrent Research in Pharmacology and Drug Discovery PMID: 35146421\nComparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons?\nClinical Gastroenterology and Hepatology PMID: 35850410\nImmunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.\nAlimentary Pharmacology & Therapeutics PMID: 35315101\nThe serum-based Endoscopic Healing Index can monitor therapeutic response in Crohn’s disease.\nJournal of Crohn’s and Colitis PMID: 37178692\nBeyond discrimination: a call for comprehensive assessment of clinical prediction models in inflammatory bowel disease.\nInflammatory Bowel Diseases PMID: 38460148\nUstekinumab and vedolizumab exposure is unaffected by pharmacogenetic determinants of anti-TNFs pharmacokinetics.\nInflammatory Bowel Diseases accepted\n\n\n\n\n\nTailoring multi-omics to inflammatory bowel diseases: all for one and one for all.\nJournal of Crohn’s and Colitis PMID: 35150242\nLongitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.\nAlimentary Pharmacology & Therapeutics PMID: 35484689\nEvaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s disease.\nTherapeutic Advances in Gastroenterology PMID: 37655059\nAdalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center.\nEuropean Journal of Gastroenterology and Hepatology PMID: 36062494\nTranslating results from VARSITY to real world: adalimumab vs vedolizumab as first-line biological in moderate to severe IBD.\nInflammatory Bowel Diseases PMID: 34751766\nThe effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases.\nBritish Journal of Clinical Pharmacology PMID: 33604964"
  },
  {
    "objectID": "publications.html#as-a-first-author",
    "href": "publications.html#as-a-first-author",
    "title": "Publications",
    "section": "",
    "text": "Breaking the therapeutic ceiling in drug development in ulcerative colitis.\nThe Lancet Gastroenterology and Hepatology PMID: 34019798\nUtility of the serum-based Endoscopic Healing Index in monitoring therapeutic response in ulcerative colitis.\nThe American Journal of Gastroenterology PMID: 37753938\nCalibration, clinical utility and specificity of clinical decision support tools in inflammatory bowel disease.\nin revision\nReal-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis.\nJournal of Crohn’s and Colitis PMID: 3533353\nReal-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study.\nInflammatory Bowel Diseases PMID: 38215029 Analysis notebook\nBest practice for therapeutic drug monitoring of infliximab: position statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.\nTherapeutic Drug Monitoring accepted\nMonitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?\nCurrent Opinion in Pharmacology PMID: 33039940\nBiomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises.\nCurrent Research in Pharmacology and Drug Discovery PMID: 35146421\nComparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons?\nClinical Gastroenterology and Hepatology PMID: 35850410\nImmunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.\nAlimentary Pharmacology & Therapeutics PMID: 35315101\nThe serum-based Endoscopic Healing Index can monitor therapeutic response in Crohn’s disease.\nJournal of Crohn’s and Colitis PMID: 37178692\nBeyond discrimination: a call for comprehensive assessment of clinical prediction models in inflammatory bowel disease.\nInflammatory Bowel Diseases PMID: 38460148\nUstekinumab and vedolizumab exposure is unaffected by pharmacogenetic determinants of anti-TNFs pharmacokinetics.\nInflammatory Bowel Diseases accepted"
  },
  {
    "objectID": "publications.html#as-a-co-author",
    "href": "publications.html#as-a-co-author",
    "title": "Publications",
    "section": "",
    "text": "Tailoring multi-omics to inflammatory bowel diseases: all for one and one for all.\nJournal of Crohn’s and Colitis PMID: 35150242\nLongitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.\nAlimentary Pharmacology & Therapeutics PMID: 35484689\nEvaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s disease.\nTherapeutic Advances in Gastroenterology PMID: 37655059\nAdalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn’s disease: real-life cohort from a tertiary referral center.\nEuropean Journal of Gastroenterology and Hepatology PMID: 36062494\nTranslating results from VARSITY to real world: adalimumab vs vedolizumab as first-line biological in moderate to severe IBD.\nInflammatory Bowel Diseases PMID: 34751766\nThe effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases.\nBritish Journal of Clinical Pharmacology PMID: 33604964"
  },
  {
    "objectID": "publications.html#as-a-first-author-hi",
    "href": "publications.html#as-a-first-author-hi",
    "title": "Publications",
    "section": "",
    "text": "Real-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis.\nJournal of Crohn’s and Colitis PMID: 3533353\nThe serum-based Endoscopic Healing Index can monitor therapeutic response in Crohn’s disease.\nJournal of Crohn’s and Colitis PMID: 37178692\nBreaking the therapeutic ceiling in drug development in ulcerative colitis.\nThe Lancet Gastroenterology and Hepatology PMID: 34019798\nBiomarker discovery for personalized therapy selection in inflammatory bowel diseases: challenges and promises.\nCurrent Research in Pharmacology and Drug Discovery PMID: 35146421\nMonitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?\nCurrent Opinion in Pharmacology PMID: 33039940\nComparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons?\nClinical Gastroenterology and Hepatology PMID: 35850410\nImmunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.\nAlimentary Pharmacology & Therapeutics PMID: 35315101"
  }
]